Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine

Vaccine

Volumn 17, Issue 7-8, 1999, Pages 660-668

  Jackman, Winthrop T ^a   Mann, Kimberly A ^a   Hoffmann, Heidi J ^a   Spaete, Richard R ^a  

^a MEDIMMUNE   (United States)

Author keywords

Epstein Barr virus; Gp350; Vaccine

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; EPSTEIN BARR VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VIRUS GLYCOPROTEIN; VIRUS RECEPTOR;

ANIMAL CELL; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CHO CELL; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOLECULAR CLONING; MUTATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR BINDING; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; CHO CELLS; CRICETINAE; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; NEUTRALIZATION TESTS; PLASMIDS; RABBITS; TRANSFECTION; VACCINES, DNA; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 0033605232     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00248-5     Document Type: Article

References (32)

1. Hoffman G.J., Lazarowitz S.G., Hayward S.D. Monoclonal antibody against a 250,000 Da glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. PNAS. 77:1980;2979-2983.
2. Thorley-Lawson D.A., Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. PNAS. 77:1980;5307-5311.
3. Thorley-Lawson D.A., Poodry C.A. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J. Virol. 43:1982;730-736.
4. Qualtiere L.F., Chase R., Pearson G.R. Purification and biologic characterization of a major Epstein-Barr virus-induced membrane glycoprotein. J. Immunol. 129:1982;814-818.
5. Finerty S., Tarlton J., Mackett M., Conway M., Arrand J.R., Watkins P.E., Morgan A.J. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J. Gen. Virol. 73:1992;449-453.
6. Morgan A.J., Allison A.C., Finerty S., Scullion F.T., Byars N.E., Epstein M.A. Validation of a first-generation Epstein-Barr Virus vaccine preparation suitable for human use. J. Med. Virol. 29:1989;74-78.
7. Tanner J., Weis J., Fearon D., Whang Y., Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping and endocytosis. Cell. 50:1987;203-213.
8. Beisel C., Tanner J., Matsuo T., Thorley-Lawson D., Kedsy F., Kieff E. Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene. J. Virol. 54:1985;665-674.
9. Biggin M., Farrell P.J., Barrell B.G. Transcription and DNA sequence of the BamHI L fragment of B95-8 Epstein-Barr virus. EMBO J. 3:1984;1083-1090.
10. Whang Y., Silberklang M., Morgan A., Munshi S., Lenny A.B., Ellis R.W., Keiff E. Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells. J. Virol. 61:1987;1796-1807.
11. Madej M., Conway M.J., Morgan A.J., Sweet J., Wallace L., Qualtiere L.F., Arrand J.R., Mackett M. Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system. Vaccine. 10:1992;777-782.
12. Hessing M., van Schijndel H.B., van Grunsven W.M.J., Wolf H., Middeldorp J.M. Purification and quantification of recombinant Epstein-Barr viral glycoproteins gp350/220 from Chinese hamster ovary cells. J. Chromatog. 599:1992;267-272.
13. Ragot T., Finerty S., Watkins P.E., Perricaudet M., Morgan A.J. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J. Gen. Virol. 74:1993;501-507.
14. Gu S.-Y., Huang T.-M., Ruan L., Miao Y.-H., Lu H., Chu C.-M., Motz M., Wolf H. First EBV vaccine trial in humans using recombinant Vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand. 84:1995;171-177.
15. Mackett M., Arrand J.R. Recombinant vaccinia virus induces neutralizing antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO J. 4:1985;3229-3234.
16. Messing J. New M13 vectors for cloning. Meth. Enzymol. 101:1983;20.
17. Emini E.A., Schleif W.A., Armstrong M.E., Silberklang M., Schultz L.D., Lehman D., Maigetter R.Z., Qualtiere L.F., Pearson G.R., Ellis R.W. Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine. Virology. 166:1988;387-393.
18. Qualtiere L.F., Decoteau J.F., Nasr-el-din M.H. Epitope mapping of the major Epstein-Barr Virus outer envelope glycoprotein gp350/220. J. Gen. Virol. 68:1987;535-543.
19. Petzer A.L., Schulz T.F., Stauder R., Eigentler A., Myones B.L., Dierich M.P. Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion. Immunology. 63:1988;47-53.
20. Moss D.J., Pope J.H. Assay of the infectivity of Epstein-Barr Virus by transformation of human leucocytes in vitro. J. Gen. Virol. 17:1972;233-236.
21. Motz M., Deby G., Jilg W., Wolf H. Expression of the Epstein-Barr virus major membrane proteins in Chinese hamster ovary cells. Gene. 44:1986;353-359.
22. Motz M., Deby G., Wolf H. Truncated versions of the two major Epstein-Barr viral glycoproteins (gp250/350) are secreted by recombinant Chinese hamster ovary cells. Gene. 58:1987;149-154.
23. Aebi M., Hornig H., Padgett R.A., Reiser J., Weissmann C. Sequence requirements for splicing of higher eukaryotic nuclear pre-mRNA. Cell. 47:1986;555-565.
24. Norton P.A. Alternative pre-mRNA splicing: factors involved in splice site selection. J. Cell Sci. 107:1994;1-7.
25. Manservigi R., Grossi M.P., Gualandri R., Balboni P.G., Marchini A., Rotola A., Rimessi P., DiLuca D., Cassai E., Barbanti-Brodano G. Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector. J. Virol. 64:1990;431-436.
26. Zhang P.-F., Klutch M., Armstrong G., Qualtiere L., Pearson G., Marcus-Sekura C.J. Mapping of the epitopes of Epstein-Barr virus gp350 using monoclonal antibodies and recombinant proteins expressed in Escherichia coli defines three antigenic determinants. J. Gen. Virol. 72:1991;2747-2755.
27. Tanner J., Whang Y., Sample J., Sears A., Kieff E. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J. Virol. 62:1988;4452-4464.
28. Emini E.A., Schleif W.A., Silberklang M., Lehman D., Ellis R.W. Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge. J. Med. Virol. 27:1989;120-123.
29. Epstein M.A., Randle B.J., Finerty S., Kirkwood J.K. Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clin. Exp. Immunol. 63:1986;485-490.
30. Khyatti M., Stefanescu I., Blagdon M., Menezes J. Epstein-Barr virus gp350-specific antibody titers and antibody-dependent cellular cytoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets. J. Infect. Dis. 170:1994;1439-1447.
31. The Celltech Glutamine Synthetase Gene Amplification System: A Manual of Operating Procedures. Version 1: For Use with Chinese Hamster Ovary (CHO) Cells (Revision 5). Lonza Biologics, 1992.
32. Chomczynski P., Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.